@article{425e0223964548c0abe2ac0bf767d6c3,
title = "Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme",
author = "Peereboom, \{David M.\} and Shepard, \{Dale R.\} and Ahluwalia, \{Manmeet S.\} and Brewer, \{Cathy J.\} and Neeraj Agarwal and Stevens, \{Glen H. J.\} and Suh, \{John H.\} and Toms, \{Steven A.\} and Vogelbaum, \{Michael A.\} and Weil, \{Robert J.\} and Paul Elson and Barnett, \{Gene H.\}",
note = "Approximately 40-50\% of glioblastomas (GBM) overexpress epidermal growth factor receptor (EGFR). Erlotinib is a specific and potent EGFR tyrosine kinase inhibitor active against refractory GBM. Patients with non-small cell lung cancer and ≥grade 2 erlotinib-induced rash have improved survival.",
year = "2010",
month = may,
day = "1",
doi = "10.1007/S11060-009-0067-2",
language = "American English",
volume = "98",
journal = "Journal of neuro-oncology",
}